Distalmotion announced today the first closing of its USD 150 million financing. This significant fundraise reinforces the confidence of its existing investors led by Revival Healthcare Capital.
Dexter, Distalmotion’s robotic platform, is in day-to-day clinical use in Europe, successfully treating patients across a multitude of complex and high-volume procedures in general surgery, gynecology, urology. This funding will enable the way for US Food and Drug Administration (FDA) approval and to continue acceleration of clinical experience in Europe.
“Dexter allows for ‘on-demand robotics’ and gives surgeons access to the benefits of both robotic and laparoscopic surgery, enabling best-in-class minimally invasive care for the patients,” explained Distalmotion CEO Michael Friedrich. “Surgeons can choose to operate entire procedures robotically, or they can leverage the ability to easily switch between the robotic and laparoscopic modalities to perform specialized tasks such as stapling with their preferred and trusted instruments. Surgeons are therefore empowered with choice and control.”